Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials

Ophthalmology

Volumn 122, Issue 4, 2015, Pages 809-816

  Grunwald, Juan E ^a   Pistilli, Maxwell ^a   Ying, Gui Shuang ^a   Maguire, Maureen G ^a   Daniel, Ebenezer ^a   Martin, Daniel F ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; ARMS2 PROTEIN, HUMAN; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H, HUMAN; HTRA1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN; SERINE PROTEINASE; TLR3 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 3; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CONTROLLED STUDY; DIGITAL COLOR PHOTOGRAPHY; EPIRETINAL MEMBRANE; EYE PHOTOGRAPHY; FEMALE; FLUORESCEIN ANGIOGRAM; FLUORESCENCE ANGIOGRAPHY; GEOGRAPHIC ATROPHY; GROWTH RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SUBRETINAL NEOVASCULARIZATION; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; GENETICS; INTRAVITREAL DRUG ADMINISTRATION; MULTICENTER STUDY; PATHOLOGY; PHOTOGRAPHY; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; VISUAL ACUITY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BEVACIZUMAB; COHORT STUDIES; COMPLEMENT C3; COMPLEMENT FACTOR H; FEMALE; FLUORESCEIN ANGIOGRAPHY; GEOGRAPHIC ATROPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; PHOTOGRAPHY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; RANIBIZUMAB; SERINE ENDOPEPTIDASES; TOLL-LIKE RECEPTOR 3; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84925308592     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.11.007     Document Type: Article

References (30)

1. D.S. Friedman, B.J. O'Colmain, and B. Muñoz Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 2004 564 572
2. P.J. Rosenfeld, D.M. Brown, and J.S. Heier Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
3. D.M. Brown, P.K. Kaiser, and M. Michels Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
4. P.J. Rosenfeld, A.A. Moshfeghi, and C.A. Puliafito Optical coherence tomography after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmic Surg Lasers Imaging 36 2005 331 335
5. R.L. Avery, D.J. Pieramici, and M.D. Rabena Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 2006 363 372
6. CATT Research Group D.F. Martin, M.G. Maguire, and G.S. Ying Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
7. P.J. Rosenfeld, H. Shapiro, L. Tuomi MARINA and ANCHOR Study Groups Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials Ophthalmology 118 2011 523 530
8. The CATT Research Group Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2-year results Ophthalmology 119 2012 1388 1398
9. J.E. Grunwald, E. Daniel, G.S. Ying CATT Research Group Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials Ophthalmology 119 2012 1634 1641
10. G.J. Jaffe, D.F. Martin, and C.A. Toth Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials Ophthalmology 120 2013 1860 1870
11. J.E. Grunwald, E. Daniel, J. Huang CATT Research Group Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials Ophthalmology 121 2014 150 161
12. Rasband WS. ImageJ. US National Institutes of Health, Bethesda, MD. Available at: http://imagej.nih.gov/ij/. 1997-2014. Accessed December 9, 2014.
13. F.C. DeCroos, C.A. Toth, S.S. Stinnett for the CATT Research Group Optical coherence tomography grading reproducibility during the Comparison of Age-Related Macular Degeneration Treatments Trials Ophthalmology 119 2012 2549 2557
14. S.A. Hagstrom, G.-S. Ying, G.J.T. Pauer The CATT Research Group Pharmacogenetics for genes associated with age-related macular degeneration (AMD) in the Comparison of AMD Treatments Trials (CATT) Ophthalmology 120 2013 593 599
15. R. Reynolds, B. Rosner, and J.M. Seddon Dietary omega-3 fatty acids, other fat intake, genetic susceptibility, and progression to incident geographic atrophy Ophthalmology 120 2013 1020 1028
16. Z. Yang, C. Stratton, and P.J. Francis Toll-like receptor 3 and geographic atrophy in age-related macular degeneration N Engl J Med 359 2008 1456 1463
17. W.J. Feuer, Z. Yehoshua, and G. Gregori Square root transformation of geographic atrophy area measurements to eliminate dependence of growth rates on baseline lesion measurements: a reanalysis of age-related eye disease study report no. 26 JAMA Ophthalmol 131 2013 101 102
18. A. Domalpally, R.P. Danis, and J. White Circularity index as a risk factor for progression of geographic atrophy Ophthalmology 120 2013 2666 2671
19. Z. Yehoshua, C.A. Filho, and R.P. Nunes Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration. The COMPLETE Study Ophthalmology 121 2014 693 701
20. N. Joachim, P. Mitchell, and A. Kifley Incidence and progression of geographic atrophy: observations from a population-based cohort Ophthalmology 120 2013 2042 2050
21. R. Klein, S.M. Meuer, M.D. Knudtson, and B.E. Klein The epidemiology of progression of pure geographic atrophy: the Beaver Dam Eye Study Am J Ophthalmol 146 2008 692 699
22. A.S. Lindblad, P.C. Lloyd, T.E. Clemons Age-Related Eye Disease Study Research Group Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26 Arch Ophthalmol 127 2009 1168 1174
23. J. Caire, S. Recalde, A. Velazquez-Villoria for the Spanish Multicenter Group on AMD Growth of geographic atrophy on fundus autofluorescence and polymorphisms of CFH, CFB, C3, FHR1-3, and ARMS2 in age-related macular degeneration JAMA Ophthalmol 132 2014 528 534
24. H.P.N. Scholl, M. Fleckenstein, and L.G. Fritsche CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD PLoS One 4 2009 e7418
25. J.S. Sunness, E. Margalit, and D. Srikumaran The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials Ophthalmology 114 2007 271 277
26. M.M. Mauschitz, S. Fonseca, P. Chang GAP Study Group Topography of geographic atrophy in age-related macular degeneration Invest Ophthalmol Vis Sci 53 2012 4932 4939
27. D.S. McLeod, R. Grebe, and I. Bhutto Relationship between RPE and choriocapillaris in age-related macular degeneration Invest Ophthalmol Vis Sci 50 2009 4982 4991
28. M. Saint-Geniez, T. Kurihara, and E. Sekiyama An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris Proc Natl Acad Sci U S A 106 2009 18751 18756
29. N. Lois, V. Mcbain, and E. Abdelkader Retinal pigment epithelial atrophy in patients with exudative age-related macular degeneration undergoing anti-vascular endothelial growth factor therapy Retina 33 2013 13 22
30. M. Young, L. Chui, and N. Fallah Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration Retina 34 2014 1308 1315